These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1617625)

  • 1. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
    Jekunen A; Vick J; Sanga R; Chan TC; Howell SB
    Cancer Res; 1992 Jul; 52(13):3566-71. PubMed ID: 1617625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipyridamole enhancement of etoposide sensitivity.
    Howell SB; Hom DK; Sanga R; Vick JS; Chan TC
    Cancer Res; 1989 Aug; 49(15):4147-53. PubMed ID: 2545335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.
    Marverti G; Andrews PA
    Clin Cancer Res; 1996 Jun; 2(6):991-9. PubMed ID: 9816260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
    Jekunen AP; Christen RD; Shalinsky DR; Howell SB
    Br J Cancer; 1994 Feb; 69(2):299-306. PubMed ID: 7905279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro.
    Shalinsky DR; Andreeff M; Howell SB
    Cancer Res; 1990 Dec; 50(23):7537-43. PubMed ID: 1979245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Naredi P; Heath DD; Enns RE; Howell SB
    Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
    Holzer AK; Katano K; Klomp LW; Howell SB
    Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro.
    Jekunen AP; Shalinsky DR; Hom DK; Albright KD; Heath D; Howell SB
    Biochem Pharmacol; 1993 May; 45(10):2079-85. PubMed ID: 8512589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
    Howell SB; Hom D; Sanga R; Vick JS; Abramson IS
    Cancer Res; 1989 Jun; 49(12):3178-83. PubMed ID: 2720673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
    Andrews PA; Albright KD
    Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-Péotti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cisplatin resistance in human malignant melanoma cells.
    McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
    Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
    Melvik JE; Pettersen EO
    Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
    Chen G; Zeller WJ
    Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin.
    Cemazar M; Sersa G; Miklavcic D
    Anticancer Res; 1998; 18(6A):4463-6. PubMed ID: 9891510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.